Atara Biotherapeutics Shares Gain 5%

Shares of Atara Biotherapeutics, Inc. (ATRA) are gaining over 5% on Friday morning despite not stock-related news to drive the shares.

ATRA is currently trading at $15.05, up $0.82 or 5.76%, on the Nasdaq. The stock has traded between $11.81 and $21.85 in the 52-week period.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company that develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT